Share on StockTwits

Stock analysts at Sterne Agee hoisted their price target on shares of Allergan (NYSE:AGN) to $185.00 in a report issued on Monday, AR Network reports. Sterne Agee’s price target suggests a potential upside of 8.88% from the stock’s previous close.

Shares of Allergan (NYSE:AGN) traded up 0.72% on Monday, hitting $169.91. The stock had a trading volume of 2,873,585 shares. Allergan has a one year low of $81.33 and a one year high of $170.05. The stock’s 50-day moving average is $135.9 and its 200-day moving average is $115.0. The company has a market cap of $50.713 billion and a P/E ratio of 51.75.

Allergan (NYSE:AGN) last announced its earnings results on Tuesday, February 4th. The company reported $1.12 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.34 by $0.22. The company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $1.65 million. During the same quarter in the prior year, the company posted $1.15 earnings per share. The company’s quarterly revenue was up 14.4% on a year-over-year basis. On average, analysts predict that Allergan will post $5.47 earnings per share for the current fiscal year.

In other Allergan news, EVP Scott Sherman sold 14,500 shares of the stock on the open market in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $155.82, for a total value of $2,259,390.00. Following the transaction, the executive vice president now directly owns 8,223 shares of the company’s stock, valued at approximately $1,281,308. The sale was disclosed in a filing with the SEC, which is available at this link.

Other equities research analysts have also recently issued reports about the stock. Analysts at Stifel Nicolaus downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research note on Monday, April 28th. They now have a $125.00 price target on the stock. Separately, analysts at Edward Jones downgraded shares of Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday, April 23rd. Finally, analysts at Piper Jaffray raised their price target on shares of Allergan from $109.00 to $164.00 in a research note on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. Allergan has an average rating of “Hold” and an average price target of $140.23.

Allergan, Inc is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.